These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 27157418

  • 21. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K, Häußler V, Havla J, Hellwig K, Hümmert MW, Kleiter I, Klotz L, Krumbholz M, Kümpfel T, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Tumani H, Wildemann B, Trebst C, Neuromyelitis Optica Study Group (NEMOS).
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [Abstract] [Full Text] [Related]

  • 22. [NMO spectrum disorders and anti AQP4 antibody].
    Takai Y, Misu T, Takahashi T, Nakashima I, Fujihara K.
    Brain Nerve; 2013 Apr; 65(4):333-43. PubMed ID: 23568981
    [Abstract] [Full Text] [Related]

  • 23. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.
    J Neurol; 2016 Jan; 263(1):140-9. PubMed ID: 26530512
    [Abstract] [Full Text] [Related]

  • 24. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, Wildemann B, in cooperation with the Neuromyelitis Optica Study Group (NEMOS).
    J Neuroinflammation; 2016 Nov 01; 13(1):281. PubMed ID: 27802825
    [Abstract] [Full Text] [Related]

  • 25. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C, Marrodan M, González A, Chertcoff A, Osa Sanz E, Chaves H, Schteinschnaider A, Correale J, Farez MF.
    Mult Scler Relat Disord; 2018 Oct 01; 25():246-250. PubMed ID: 30144694
    [Abstract] [Full Text] [Related]

  • 26. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM, Waters P, Woodhall M, Kim JY, Kim JE, Yang JW, Kim JS, Sung JJ, Park KS, Lee KW.
    Mult Scler; 2013 Jul 01; 19(8):1060-7. PubMed ID: 23329699
    [Abstract] [Full Text] [Related]

  • 27. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T.
    J Neuroinflammation; 2015 Mar 08; 12():46. PubMed ID: 25889963
    [Abstract] [Full Text] [Related]

  • 28. [Clinical concept, etiology and pathology of neuromyelitis optica].
    Kurosawa K, Fujihara K.
    Nihon Rinsho; 2014 Nov 08; 72(11):1897-902. PubMed ID: 25518368
    [Abstract] [Full Text] [Related]

  • 29. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
    Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B.
    J Neurol Sci; 2011 Jul 15; 306(1-2):82-90. PubMed ID: 21550068
    [Abstract] [Full Text] [Related]

  • 30. Diagnosis and treatment of neuromyelitis optica.
    Wingerchuk DM.
    Neurologist; 2007 Jan 15; 13(1):2-11. PubMed ID: 17215722
    [Abstract] [Full Text] [Related]

  • 31. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders.
    Sato DK, Nakashima I, Takahashi T, Misu T, Waters P, Kuroda H, Nishiyama S, Suzuki C, Takai Y, Fujihara K, Itoyama Y, Aoki M.
    Neurology; 2013 Jun 11; 80(24):2210-6. PubMed ID: 23677744
    [Abstract] [Full Text] [Related]

  • 32. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J.
    Curr Opin Neurol; 2019 Feb 11; 32(1):111-114. PubMed ID: 30562266
    [Abstract] [Full Text] [Related]

  • 33. Neuromyelitis optica and aquaporin-4 (AQP4) autoantibodies in consecutive optic neuritis patients in Southern Finland.
    Siuko M, Tienari PJ, Saastamoinen KP, Atula S, Miettinen A, Kivelä T, Setälä K.
    Acta Ophthalmol; 2014 Jun 11; 92(4):387-91. PubMed ID: 23773223
    [Abstract] [Full Text] [Related]

  • 34. Neuromyelitis optica and astrocytic damage in its pathogenesis.
    Fujihara K.
    J Neurol Sci; 2011 Jul 15; 306(1-2):183-7. PubMed ID: 21396661
    [Abstract] [Full Text] [Related]

  • 35. Neuromyelitis optica spectrum disorders: still evolving and broadening.
    Fujihara K.
    Curr Opin Neurol; 2019 Jun 15; 32(3):385-394. PubMed ID: 30893099
    [Abstract] [Full Text] [Related]

  • 36. Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD.
    Paolilo RB, Rimkus CM, da Paz JA, Apostolos-Pereira SL, Callegaro D, Sato DK.
    Mult Scler Relat Disord; 2022 Dec 15; 68():104215. PubMed ID: 36257150
    [Abstract] [Full Text] [Related]

  • 37. Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study.
    Asgari N, Skejoe HP, Lillevang ST, Steenstrup T, Stenager E, Kyvik KO.
    BMC Neurol; 2013 Apr 08; 13():33. PubMed ID: 23566260
    [Abstract] [Full Text] [Related]

  • 38. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
    Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, Thompson CB, Pardo CA, Calabresi PA, Levy M, Izbudak I.
    Mult Scler; 2016 Mar 08; 22(3):302-11. PubMed ID: 26209588
    [Abstract] [Full Text] [Related]

  • 39. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
    Castro-Suarez S, Guevara-Silva E, Osorio-Marcatinco V, Alvarez-Toledo K, Meza-Vega M, Caparó-Zamalloa C.
    Mult Scler Relat Disord; 2022 Aug 08; 64():103919. PubMed ID: 35691236
    [Abstract] [Full Text] [Related]

  • 40. NMO-IgG: a specific biomarker for neuromyelitis optica.
    Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA.
    Dis Markers; 2006 Aug 08; 22(4):197-206. PubMed ID: 17124341
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.